Funding
Research was supported by grants from NIAID of the NIH to (R01-AI153602 and R21-AI145400 to V.D.M., R24 AI120942 to S.C.W.)). A.L.R. was supported by a UTMB Institute for Human Infection and Immunity grant and the Sealy and Smith Foundation. Research was also supported by STARs Award provided by the University of Texas System and Burroughs Welcome Fund Investigators in Pathogenesis grant to V.D.M. Data Acquisition award provided by the Institute for Human Infections and Immunity at UTMB to M.N.V. Trainee funding provided by NIAID of the NIH to M.N.V. (T32-AI060549), C.S. (T32AI007526), and REA (T32AI007526). Experiments and analysis were provided by the Mass Spectrometry Facility at the University of Texas Medical Branch (https://www.utmb.edu/MSF) and is funded in part by CPRIT RP250644 (WKR). Figures were created with BioRender.com
Ethics declarations
Competing interests
V.D.M. has filed a patent on the reverse genetic system and reporter SARS-CoV-2. M.N.V. and V.D.M. have filed a provisional patent on a stabilized SARS-CoV-2 spike protein. Other authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Source data
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Reprints and permissions
About this article
Cite this article
Vu, M.N., Alvarado, R.E., Morris, D.R. et al. Loss-of-function mutation in Omicron variants reduces spike protein expression and attenuates SARS-CoV-2 infection. Nat Commun (2026). https://doi.org/10.1038/s41467-026-76680-4
Download citation
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41467-026-76680-4